Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution

Table 4 Factors at Enrollment associated with Overall Survivals

Variables	Univariate analysis			Multivariate analysis
	Odds ratio	95%CI	p value	Odds ratio	95%CI	p value
age (per 1 year)	1.02	0.96–1.10	0.590
male (v.s. female)	0.79	0.32–1.94	0.608
head (v.s.body and tail)	0.75	0.30–1.83	0.520
CA19-9 > 400 U/ml at enrollment	3.08	1.22–7.79	0.018	2.52	1.05–6.63	0.043
diameter > 30 mm at enrollment	1.85	0.76–4.48	0.175	1.78	0.72–4.41	0.212
BRPV at enrollment (v.s. without BRPV)	1.79	0.59–5.36	0.301
NL at enrollment (per ratio)	1.32	0.79–1.13	0.200	1.24	0.52–1.19	0.297

Abbreviations: CA19-9 carbohydrate antigen 19–9, BRPV borderline resectable pancreatic cancer with portal vein involvement, NL neutrophil to leukocyte ratio

ISSN: 1471-2407